Search International and National Patent Collections

1. (WO2017034906) SUBCUTANEOUS ANTI-HLA-DR MONOCLONAL ANTIBODY FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES

Pub. No.:    WO/2017/034906    International Application No.:    PCT/US2016/047483
Publication Date: Fri Mar 03 00:59:59 CET 2017 International Filing Date: Fri Aug 19 01:59:59 CEST 2016
IPC: A61K 39/395
A61K 51/10
C07K 16/28
C07K 16/30
C07K 16/46
Applicants: IMMUNOMEDICS, INC.
Inventors: GOLDENBERG, David M.
WEGENER, William A.
Title: SUBCUTANEOUS ANTI-HLA-DR MONOCLONAL ANTIBODY FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES
Abstract:
The present invention concerns compositions and methods of use of anti-HLA-DR antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease. The subcutaneously administered anti-HLA-DR antibody is effective to treat hematologic cancer or autoimmune disease in patients that have relapsed from or are refractory to standard therapies for hematologic cancer or autoimmune disease, such as administration of anti-CD20 antibodies, such as rituximab.